Cannabis: WHO just acknowledged historical misjudgment and heads towards global policy update

After thoroughly assessing Cannabis, THC and CBD in June, the WHO has just recognized its historical misjudgment that led to the placement of Cannabis medicines among heroin or fentanyl derivates, and will consider an international change of scheduling to adequate policies with evidence. #ECDD40

40th ECDD meeting in Geneva: pivotal moment for global Cannabis policies.

This week in Geneva for the first time ever, the WHO drugs committee has heard the voices of doctors, patients, and researchers, and started to weigh the harms and benefits of Cannabis neutrally.

Crimson paper #3. The review(s).

Pre & Critical reviews: insights into the processes of the WHO scientific abuse liability assessment for drugs.

Cannabis review by the WHO: all you need to know

In 2018 for the first time, the World Health Organization is assessing the medical uses and harms of Cannabis, and will recommend the suitable classification to be applied internationally. We promote an objective and independent assessment, that recognizes and acknowledges modern research on Cannabis. Support us!

Pin It on Pinterest